Progyny (PGNY) Stock Price, News & Analysis

Company Overview

Progyny, Inc. is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company’s services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States. The company was founded in 2015 and became a publicly traded company in 2019. Progyny is led by Chief Executive Officer Pete Anevski.

Key Stats

• Today's Range: $24.80 to $25.24
• 50-Day Range: $24.79 to $31.59
• 52-Week Range: $16.10 to $33.06
• Volume: 140,073 shs
• Average Volume: 1.40 million shs
• Market Capitalization: $1.95 billion
• P/E Ratio: 27.49
• Dividend Yield: N/A
• Price Target: $34.36
• Consensus Rating: Moderate Buy

Progyny Stock Analysis - MarketRank™

Progyny scored higher than 88% of companies evaluated by MarketBeat, and ranked 72nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Progyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 9 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Progyny has a consensus price target of $34.36, representing about 38.6% upside from its current price of $24.79.

Amount of Analyst Coverage

Progyny has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 13.60%

Earnings Growth

Earnings for Progyny are expected to grow by 13.60% in the coming year, from $1.25 to $1.42 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Progyny is 26.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.75.

Price to Earnings Ratio vs. Sector

The P/E ratio of Progyny is 26.95, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.78.

Price to Earnings Growth Ratio

Progyny has a PEG Ratio of 1.76. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Progyny has a P/B Ratio of 4.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.81% of the float of Progyny has been sold short.

Short Interest Ratio / Days to Cover

Progyny has a short interest ratio ("days to cover") of 4.61.

Change versus previous month

Short interest in Progyny has recently increased by 5.76%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Progyny does not currently pay a dividend.

Dividend Growth

Progyny does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.00

News Sentiment

Progyny has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Progyny this week, compared to 4 articles on an average week.

MarketBeat Follows

3 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $423,178.00 in company stock.

Percentage Held by Insiders

9.90% of the stock of Progyny is held by insiders.

Percentage Held by Institutions

94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:PGNY
• CIK: 1551306
• Web: www.progyny.com
• Phone: 212-888-3124
• Fax: N/A
• Employees: 856
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Progyny: $34.36
• High Price Target: $40.00
• Low Price Target: $30.00
• Potential Upside/Downside: +36.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.92
• Trailing P/E Ratio: 27.42
• Forward P/E Ratio: 20.16
• P/E Growth: 1.76
• Net Income: $58.52 million
• Net Margins: 6.00%
• Pretax Margin: 9.14%
• Return on Equity: 15.98%
• Return on Assets: 10.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.14
• Quick Ratio: 2.14

Sales & Book Value

• Annual Sales: $1.31 billion
• Price / Sales: 1.48
• Cash Flow: $0.73 per share
• Price / Cash Flow: 34.67
• Book Value: $5.99 per share
• Price / Book: 4.21

Miscellaneous

• Outstanding Shares: 76,727,000
• Free Float: 69,131,000
• Market Cap: $1.93 billion
• Optionable: Optionable
• Beta: 0.99